Delaunay, Charlotte LanieceVerdasca, NunoMonge, SusanaDomegan, LisaSève, NoémieBuda, SilkeMeijer, AdamLucaccioni, HéloïseTorrijos, Miriam LópezMcKenna, AdeleEnouf, VincentDürrwald, RalfIn't Velt, ElineLaiglesia, Mª Ángel de ValcárcelBennett, CharleneMasse, ShirleyErdwiens, AnnikaHooiveld, MarietteMlinarić, IvanTúri, GergőRodrigues, Ana PaulaMartínez-Baz, IvánLazar, MihaelaLatorre-Margalef, NeusBorges, VitorKaczmarek, MarlenaBacci, SabrinaKissling, EstherEuropean primary care VE group2026-01-202026-01-202025-05-21Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111/irv.701201750-2640http://hdl.handle.net/10400.18/10721VEBIS Primary Care Vaccine Effectiveness Group: Portugal: Ausenda Machado, João Santos (Epidemiology Department, National Institute of Health Dr. Ricardo Jorge), Raquel Guiomar, Licínia Gomes, Camila Henriques and Daniela Dias (Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge).We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.engCOVID‐19SARS‐CoV‐2Vaccine EffectivenessEuropeInfecções RespiratóriasCuidados de Saúdejournal article10.1111/irv.701201750-265940395132